234 related articles for article (PubMed ID: 36569949)
1. Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses.
Qiao Y; Zhan Y; Zhang Y; Deng J; Chen A; Liu B; Zhang Y; Pan T; Zhang W; Zhang H; He X
Front Immunol; 2022; 13():992062. PubMed ID: 36569949
[TBL] [Abstract][Full Text] [Related]
2. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
3. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
4. Novel Synthetic Lipopeptides as Potential Mucosal Adjuvants Enhanced SARS-CoV-2 rRBD-Induced Immune Response.
Mao L; Liu C; Liu JY; Jin ZL; Jin Z; Xue RY; Feng R; Li GC; Deng Y; Cheng H; Zou QM; Li HB
Front Immunol; 2022; 13():833418. PubMed ID: 35356002
[TBL] [Abstract][Full Text] [Related]
5. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice.
Barbey C; Su J; Billmeier M; Stefan N; Bester R; Carnell G; Temperton N; Heeney J; Protzer U; Breunig M; Wagner R; Peterhoff D
Eur J Pharm Biopharm; 2023 Nov; 192():41-55. PubMed ID: 37774890
[TBL] [Abstract][Full Text] [Related]
7. A SARS-CoV-2 nanoparticle vaccine based on chemical conjugation of loxoribine and SpyCatcher/SpyTag.
Yan W; Yu W; Shen L; Xiao L; Qi J; Hu T
Int J Biol Macromol; 2023 Dec; 253(Pt 5):127159. PubMed ID: 37778577
[TBL] [Abstract][Full Text] [Related]
8. Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.
Xiao L; Yu W; Shen L; Yan W; Qi J; Hu T
ACS Appl Mater Interfaces; 2023 Aug; 15(30):35895-35905. PubMed ID: 37466148
[TBL] [Abstract][Full Text] [Related]
9. Self-Assembling Sulfated
Zhang S; Fan W; Ding C; Zhang M; Liu S; Liu W; Tang Z; Huang C; Yan L; Song S
ACS Appl Mater Interfaces; 2024 Apr; 16(15):18591-18607. PubMed ID: 38564431
[TBL] [Abstract][Full Text] [Related]
10. TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.
Yang JX; Tseng JC; Tien CF; Lee CY; Liu YL; Lin JJ; Tsai PJ; Liao HC; Liu SJ; Su YW; Hsu LC; Chen JK; Huang MH; Yu GY; Chuang TH
Int J Biol Sci; 2023; 19(9):2897-2913. PubMed ID: 37324951
[TBL] [Abstract][Full Text] [Related]
11. Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.
Li H; Guo L; Zheng H; Li J; Zhao X; Li J; Liang Y; Yang F; Zhao Y; Yang J; Xue M; Zuo Y; Zhou J; Chen Y; Yang Z; Li Y; Jin W; Shi H; He Z; Li Q; Liu L
Bioconjug Chem; 2021 May; 32(5):1034-1046. PubMed ID: 33951913
[TBL] [Abstract][Full Text] [Related]
12. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
Front Immunol; 2022; 13():974364. PubMed ID: 36159845
[TBL] [Abstract][Full Text] [Related]
13. Self-Adjuvanting Protein Vaccine Conjugated with a Novel Synthetic TLR4 Agonist on Virus-Like Liposome Induces Potent Immunity against SARS-CoV-2.
Ding D; Wen Y; Liao CM; Yin XG; Zhang RY; Wang J; Zhou SH; Zhang ZM; Zou YK; Gao XF; Wei HW; Yang GF; Guo J
J Med Chem; 2023 Jan; 66(2):1467-1483. PubMed ID: 36625758
[TBL] [Abstract][Full Text] [Related]
14. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Horvath D; Temperton N; Mayora-Neto M; Da Costa K; Cantoni D; Horlacher R; Günther A; Brosig A; Morath J; Jakobs B; Groettrup M; Hoschuetzky H; Rohayem J; Ter Meulen J
Sci Rep; 2023 Mar; 13(1):4648. PubMed ID: 36944687
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.
Liao HC; Wu WL; Chiang CY; Huang MS; Shen KY; Huang YL; Wu SC; Liao CL; Chen HW; Liu SJ
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563292
[TBL] [Abstract][Full Text] [Related]
16. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
[TBL] [Abstract][Full Text] [Related]
17. Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniae.
Deng Y; Li J; Sun C; Chi H; Luo D; Wang R; Qiu H; Zhang Y; Wu M; Zhang X; Huang X; Xie L; Qin C
Adv Mater; 2022 May; 34(21):e2200443. PubMed ID: 35332581
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2.
Moshref Javadi M; Taghdisi Hosseinzadeh M; Soleimani N; Rommasi F
Microb Pathog; 2022 Sep; 170():105687. PubMed ID: 35917987
[TBL] [Abstract][Full Text] [Related]
19. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice.
Sun W; He L; Zhang H; Tian X; Bai Z; Sun L; Yang L; Jia X; Bi Y; Luo T; Cheng G; Fan W; Liu W; Li J
Signal Transduct Target Ther; 2021 Sep; 6(1):340. PubMed ID: 34504054
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
